Patents by Inventor Stephen Tran

Stephen Tran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusions of antibodies to CD38 and attenuated interferon alpha
    Patent number: 10981986
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 20, 2021
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: David S. Wilson, Jr., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
  • Discovery of enzymes from the alpha-keto acid decarboxylase family
    Patent number: 10829756
    Abstract: 2-ketoacid decarboxylase enzymes, compositions encoding for 2 ketoacid decarboxylase enzymes, and host cells comprising such enzymes or compositions are provided.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: November 10, 2020
    Assignees: The Regents of the University of California, The University of Washington
    Inventors: Justin Siegel, Steve Bertolani, Wai Shun Mak, James Liao, Stephen Tran, Ryan Marcheschi, James Thompson, David Baker
  • DISCOVERY OF ENZYMES FROM THE ALPHA-KETO ACID DECARBOXYLASE FAMILY
    Publication number: 20190010480
    Abstract: 2-ketoacid decarboxylase enzymes, compositions encoding for 2 ketoacid decarboxylase enzymes, and host cells comprising such enzymes or compositions are provided
    Type: Application
    Filed: August 29, 2016
    Publication date: January 10, 2019
    Applicant: Regents of the University of California
    Inventors: Justin Siegel, Steve Bertolani, Wai Shun Mak, James Liao, Stephen Tran, Ryan Marcheschi, James Thompson, David Baker
  • FUSIONS OF ANTIBODIES TO CD38 AND ATTENUATED INTERFERON ALPHA
    Publication number: 20170233449
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Application
    Filed: March 2, 2017
    Publication date: August 17, 2017
    Inventors: David S. Wilson, Jr., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
  • Fusions of antibodies to CD38 and attenuated interferon alpha
    Patent number: 9611322
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: April 4, 2017
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: David S. Wilson, Jr., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
  • POLYPEPTIDE CONSTRUCTS AND USES THEREOF
    Publication number: 20160367695
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Application
    Filed: June 28, 2016
    Publication date: December 22, 2016
    Inventors: David S. Wilson, Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
  • Anti-IL-23 heterodimer specific antibodies
    Patent number: 9127057
    Abstract: The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: September 8, 2015
    Assignee: Teva Pharmaceuticals Ausralia Pty Ltd
    Inventors: Adam William Clarke, Anthony G. Doyle, Matthew Pollard, Stephen Tran
  • POLYPEPTIDE CONSTRUCTS AND USES THEREOF
    Publication number: 20140248238
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Application
    Filed: April 28, 2014
    Publication date: September 4, 2014
    Applicant: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: David S. Wilson, JR., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
  • ANTI-IL-23 HETERODIMER SPECIFIC ANTIBODIES
    Publication number: 20130115166
    Abstract: The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.
    Type: Application
    Filed: July 20, 2011
    Publication date: May 9, 2013
    Applicant: CEPHALON AUSTRALIA PTY LTD.
    Inventors: Adam William Clarke, Anthony G. Doyle, Matthew Pollard, Stephen Tran